333 related articles for article (PubMed ID: 17588565)
1. Allosteric interaction of the neuromuscular blockers vecuronium and pancuronium with recombinant human muscarinic M2 receptors.
Cembala TM; Forde SC; Appadu BL; Lambert DG
Eur J Pharmacol; 2007 Aug; 569(1-2):37-40. PubMed ID: 17588565
[TBL] [Abstract][Full Text] [Related]
2. Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells.
Cembala TM; Sherwin JD; Tidmarsh MD; Appadu BL; Lambert DG
Br J Pharmacol; 1998 Nov; 125(5):1088-94. PubMed ID: 9846649
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of binding sites on cardiac muscarinic receptors induced by the neuromuscular blocking agents gallamine and pancuronium.
Dunlap J; Brown JH
Mol Pharmacol; 1983 Jul; 24(1):15-22. PubMed ID: 6135150
[TBL] [Abstract][Full Text] [Related]
4. Stabilization of antagonist binding to cardiac muscarinic acetylcholine receptors by gallamine and other neuromuscular blocking drugs.
Nedoma J; Tucek S; Danilov AF; Shelkovnikov SA
J Pharmacol Exp Ther; 1986 Jan; 236(1):219-23. PubMed ID: 3941394
[TBL] [Abstract][Full Text] [Related]
5. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor.
Steinfeld T; Mammen M; Smith JA; Wilson RD; Jasper JR
Mol Pharmacol; 2007 Aug; 72(2):291-302. PubMed ID: 17478612
[TBL] [Abstract][Full Text] [Related]
6. Regulation of M2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators.
May LT; Lin Y; Sexton PM; Christopoulos A
J Pharmacol Exp Ther; 2005 Jan; 312(1):382-90. PubMed ID: 15333678
[TBL] [Abstract][Full Text] [Related]
7. Three allosteric modulators act at a common site, distinct from that of competitive antagonists, at muscarinic acetylcholine M2 receptors.
Lanzafame A; Christopoulos A; Mitchelson F
J Pharmacol Exp Ther; 1997 Jul; 282(1):278-85. PubMed ID: 9223565
[TBL] [Abstract][Full Text] [Related]
8. The impact of orthosteric radioligand depletion on the quantification of allosteric modulator interactions.
Avlani VA; McLoughlin DJ; Sexton PM; Christopoulos A
J Pharmacol Exp Ther; 2008 Jun; 325(3):927-34. PubMed ID: 18322151
[TBL] [Abstract][Full Text] [Related]
9. Role of acidic amino acids in the allosteric modulation by gallamine of antagonist binding at the m2 muscarinic acetylcholine receptor.
Leppik RA; Miller RC; Eck M; Paquet JL
Mol Pharmacol; 1994 May; 45(5):983-90. PubMed ID: 8190113
[TBL] [Abstract][Full Text] [Related]
10. Allosteric interactions at the m1, m2 and m3 muscarinic receptor subtypes.
Lee NH; el-Fakahany EE
J Pharmacol Exp Ther; 1991 Feb; 256(2):468-79. PubMed ID: 1993991
[TBL] [Abstract][Full Text] [Related]
11. Two-state models and the analysis of the allosteric effect of gallamine at the M2 muscarinic receptor.
Ehlert FJ; Griffin MT
J Pharmacol Exp Ther; 2008 Jun; 325(3):1039-60. PubMed ID: 18305010
[TBL] [Abstract][Full Text] [Related]
12. Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors.
Hou VY; Hirshman CA; Emala CW
Anesthesiology; 1998 Mar; 88(3):744-50. PubMed ID: 9523819
[TBL] [Abstract][Full Text] [Related]
13. Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors.
Avlani V; May LT; Sexton PM; Christopoulos A
J Pharmacol Exp Ther; 2004 Mar; 308(3):1062-72. PubMed ID: 14711931
[TBL] [Abstract][Full Text] [Related]
14. Divergence of allosteric effects of rapacuronium on binding and function of muscarinic receptors.
Jakubík J; Randáková A; El-Fakahany EE; Dolezal V
BMC Pharmacol; 2009 Dec; 9():15. PubMed ID: 20038295
[TBL] [Abstract][Full Text] [Related]
15. Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist.
Langmead CJ; Fry VA; Forbes IT; Branch CL; Christopoulos A; Wood MD; Herdon HJ
Mol Pharmacol; 2006 Jan; 69(1):236-46. PubMed ID: 16207821
[TBL] [Abstract][Full Text] [Related]
16. Direct evidence that pancuronium and gallamine enhance the release of norepinephrine from the atrial sympathetic nerve by inhibiting prejunctional muscarinic receptors.
Kobayashi O; Nagashima H; Duncalf D; Chaudhry IA; Harsing LG; Foldes FF; Goldiner PL; Vizi ES
J Auton Nerv Syst; 1987 Jan; 18(1):55-60. PubMed ID: 2880888
[TBL] [Abstract][Full Text] [Related]
17. Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors.
Tränkle C; Weyand O; Voigtländer U; Mynett A; Lazareno S; Birdsall NJ; Mohr K
Mol Pharmacol; 2003 Jul; 64(1):180-90. PubMed ID: 12815174
[TBL] [Abstract][Full Text] [Related]
18. Interaction of the neuromuscular blocking drugs alcuronium, decamethonium, gallamine, pancuronium, ritebronium, tercuronium and d-tubocurarine with muscarinic acetylcholine receptors in the heart and ileum.
Nedoma J; Dorofeeva NA; Tucek S; Shelkovnikov SA; Danilov AF
Naunyn Schmiedebergs Arch Pharmacol; 1985 Apr; 329(2):176-81. PubMed ID: 4010794
[TBL] [Abstract][Full Text] [Related]
19. Changes of cooperativity between N-methylscopolamine and allosteric modulators alcuronium and gallamine induced by mutations of external loops of muscarinic M(3) receptors.
Krejcí A; Tucek S
Mol Pharmacol; 2001 Oct; 60(4):761-7. PubMed ID: 11562438
[TBL] [Abstract][Full Text] [Related]
20. New insight into active muscarinic receptors with the novel radioagonist [³H]iperoxo.
Schrage R; Holze J; Klöckner J; Balkow A; Klause AS; Schmitz AL; De Amici M; Kostenis E; Tränkle C; Holzgrabe U; Mohr K
Biochem Pharmacol; 2014 Aug; 90(3):307-19. PubMed ID: 24863257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
